Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Red Bull have parted ways with long-term team principal Christian Horner following their poor first half to the 2025 Formula ...

Every woman dreams of being a mother. Or does she really? In Karlovy Vary Film Festival contender "Out of Love," two ...

President Trump said that his administration is working with Texas state and local officials in response to fatal flash ...

Everton fan and broadcaster David Downie spoke to BBC Radio Merseyside about Dominic Calvert-Lewin's departure: "Right now we ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

DEAR MISS MANNERS: I am wondering if it would be crass or in poor taste to give a new widow a thoughtful sympathy card with ...

Turning to the CEPEP cuts, Ghany said the Government must make tough choices and is strategically spending its “political ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...